Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 24209521)

1.

Re: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Taneja SS.

J Urol. 2013 Dec;190(6):2094. doi: 10.1016/j.juro.2013.08.104. Epub 2013 Sep 7. No abstract available.

PMID:
24209521
2.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M.

Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8.

PMID:
23306100
4.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Fizazi K.

Eur J Cancer. 2014 Mar;50(5):953-62. doi: 10.1016/j.ejca.2013.11.034. Epub 2014 Jan 11.

PMID:
24424105
5.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

PMID:
22369348
6.

Prostate cancer therapy: going forwards by going backwards.

Sweeney C.

Lancet Oncol. 2013 Feb;14(2):104-5. doi: 10.1016/S1470-2045(12)70591-0. Epub 2013 Jan 8. No abstract available.

PMID:
23306099
7.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
8.

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houedé N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Lagrange JL, Chinet-Charrot P, Linassier C, Deplanque G, Beuzeboc P, Geneve J, Davin JL, Tournay E, Culine S.

Eur J Cancer. 2012 Jan;48(2):209-17. doi: 10.1016/j.ejca.2011.10.015. Epub 2011 Nov 24.

PMID:
22119204
9.
10.
12.

Re: Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Taneja SS.

J Urol. 2013 Sep;190(3):880. doi: 10.1016/j.juro.2013.05.105. Epub 2013 Jun 7. No abstract available.

PMID:
23931194
13.

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.

Eur J Cancer. 2012 Nov;48(16):2993-3000. doi: 10.1016/j.ejca.2012.05.014. Epub 2012 Jun 6.

14.

An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.

Salzberg M, Rochlitz C, Morant R, Thalmann G, Pedrazzini A, Roggero E, Schönenberger A, Knuth A, Borner M.

Onkologie. 2007 Jul;30(7):355-60. Epub 2007 Jun 27.

PMID:
17596743
15.

The current role of chemotherapy in metastatic hormone-refractory prostate cancer.

Petrylak DP.

Urology. 2005 May;65(5 Suppl):3-7; discussion 7-8. Review.

PMID:
15885271
16.

Metastatic castrate-resistant prostate cancer: dawn of a new age of management.

Masson S, Bahl A.

BJU Int. 2012 Oct;110(8):1110-4. doi: 10.1111/j.1464-410X.2012.11076.x. Epub 2012 May 7. Review.

PMID:
22564337
17.

Prolonging survival in prostate cancer: chemotherapy will have an important role.

Parker C, Emberton M.

BJU Int. 2005 Jul;96(1):2-3. No abstract available.

PMID:
15963108
18.

Hormone-refractory prostate cancer: where are we going?

Di Lorenzo G, Autorino R, Figg WD, De Placido S.

Drugs. 2007;67(8):1109-24. Review.

PMID:
17521214
19.

NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Jilani A, George E, Adler AI.

Lancet Oncol. 2012 Jun;13(6):573-4. No abstract available.

PMID:
22833888
20.

Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.

Urology. 2013 Mar;81(3):611-6. doi: 10.1016/j.urology.2012.12.025.

PMID:
23452809
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk